Apellis Pharmaceuticals prices $350M public offering of 8.75M shares at $40/share

Apellis Pharmaceuticals, Inc.

Apellis priced public offering of 8.75M shares at $40.00/share for gross proceeds of $350M.
Underwriters have 30-day option to purchase up to 1.3125M additional shares at the same price less discounts.
Estimated net proceeds of ~$330.2M, or ~$379.8M if underwriters fully exercise option.
Offering expected to close Nov. 18, 2021; J.P. Morgan, Goldman Sachs, Evercore are joint book-running managers.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.